STOCK TITAN
  1. Home
  2. News
  3. SILO

SILO Pharma Inc - SILO STOCK NEWS

IMPACT
SENTIMENT
SILO : Nasdaq
Silo Pharma Enters into Exclusive License Agreement with Medspray Pharma BV for Intranasal Technology used in SPC-15 Treatment for PTSD
IMPACT
SENTIMENT
SILO : Nasdaq
Silo Pharma to Initiate Dose-Ranging Study of Novel Intranasal Therapeutic SPC-15 for the Treatment of PTSD
IMPACT
SENTIMENT
SILO : Nasdaq
Silo Pharma Initiates Human Factor Study of SPC-15 for the Treatment of PTSD
IMPACT
SENTIMENT
SILO : Nasdaq
Silo Pharma Announces Positive Data on SPC-15 for PTSD and Prepares to File Pre-Investigational New Drug (IND) Application with FDA
IMPACT
SENTIMENT
SILO : Nasdaq
Silo Pharma Initiates Feasibility Study of SPC-15 Novel Intranasal Formulation for PTSD
IMPACT
SENTIMENT
SILO : Nasdaq
Silo Pharma Engages Clarivate for Intellectual Property and Patent Management
IMPACT
SENTIMENT
SILO : Nasdaq
Silo Pharma Reaches Positive Milestone with Nasal Formulation of SPC-15 For Anxiety, PTSD, and Stress-Related Disorders
IMPACT
SENTIMENT
SILO : Nasdaq
Psychedelics Company Silo Pharma Working On Time-Release And Dosage Ketamine Implant And Topical, Hoping To Deliver Steady Pain Relief For Four Million Fibromyalgia Sufferers
IMPACT
SENTIMENT
SILO : Nasdaq
Silo Pharma’s SPU-21 Treatment for Autoimmune Disease Awarded U.S. Patent
IMPACT
SENTIMENT
SILO : Nasdaq
Silo Pharma Signs Agreement to Develop First-in-Class Ketamine Implant Therapeutic
Stock SILO logo
SILO Pharma Inc

Nasdaq:SILO

SILO Rankings

N/A Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

SILO Stock Data

Securities and Commodity Exchanges
Finance and Insurance
Consumer Durables, Other Consumer Specialties, Finance and Insurance, Securities and Commodity Exchanges

About SILO

silo pharma inc. (nasdaq: silo), a developmental stage biopharmaceutical company, is focused on merging traditional therapeutics with psychedelic research for people suffering from indications such as post-traumatic stress disorder, fibromyalgia, alzheimer’s disease, parkinson’s disease, and other rare neurological disorders. silo’s mission is to identify assets to license and fund research that the company believes will be transformative to the wellbeing of patients and the health care industry. silo is committed to developing innovative solutions to address a variety of underserved conditions. combining silo’s resources with world-class medical research partners, the company looks to make significant advances in the medical and psychedelic space. silo works to identify and partner with leading medical universities, providing the needed financial resources to develop safe therapeutic treatments while moving cutting-edge research through the clinical stage and into commercialization.